| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Nuo Therapeutics, Inc. (AURX) has 6 insiders with recent SEC Form 4 filings, including 8 buys and 10 sells. AURX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 11.57M | $14.46M | - | |
| 10% | 5.40M | $6.75M | - | |
| CEO | 2.07M | $2.59M | - | |
| COO | 770.1K | $962.6K | - | |
| Dir | 108.3K | $135.4K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Nov 28, 2025 | Jorden David Emerson | Ceo/ CFO | Sell | 200,000 | $1.50 | $300,000.00 | -9.3% | |
| Jul 30, 2025 | Sheedy Charles E | 10% Owner | Buy | 133,333 | $1.50 | $199,999.50 | +1.2% | |
| Sep 18, 2024 | Sheedy Charles E | 10% Owner | Buy | 125,000 | $0.75 | $93,750.00 | +1.1% | |
| May 20, 2024 | Sheedy Charles E | 10% Owner | Buy | 100,000 | $0.75 | $75,000.00 | +0.9% | |
| Dec 19, 2023 | Sheedy Charles E | 10% Owner | Buy | 150,000 | $0.50 | $75,000.00 | +1.4% | |
| Aug 1, 2023 | Sheedy Charles E | 10% Owner | Buy | 62,500 | $2.00 | $125,000.00 | +0.6% | |
| Nov 9, 2022 | Jorden David Emerson | Ceo/ CFO | Sell | 162,500 | $1.50 | $243,750.00 | -0.9% | |
| Apr 29, 2022 | Sheedy Charles E | 10% Owner | Buy | 804,868 | $1.00 | $804,868.00 | +7.9% | |
| Sep 11, 2017 | Boyalife Investment Fund I, Inc. | 10% Owner | Buy | 3,150,000 | $0.22 | $699,930.00 | +180.0% | |
| Aug 10, 2017 | Jorden David Emerson | CEO, CFO | Buy | 247,500 | $0.22 | $54,994.50 | +79.9% |